Top Key Companies for Targeted Radionuclide Drug Market: POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals, RadioMedix, Inc., Convergent Therapeutics, IONETIX, Clarity Pharmaceuticals, RayzeBio, Inc, AmbioPharm, Bracco Imaging, Navidea, China Isotope & Radiation Corporation, Yantai Dongcheng, Grand Pharma, Hengrui Medicine, Yunnan Baiyao Group, SmartNuclide Biopharma, Sinotau, Hexin Pharmaceutical.
Global Targeted Radionuclide Drug Market Size was estimated at USD 329.88 million in 2022 and is projected to reach USD 474.87 million by 2028, exhibiting a CAGR of 6.26% during the forecast period.
Global Targeted Radionuclide Drug Market Overview And Scope:
The Global Targeted Radionuclide Drug Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Targeted Radionuclide Drug utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Targeted Radionuclide Drug Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Radionuclide Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Targeted Radionuclide Drug market.
Global Targeted Radionuclide Drug Market Segmentation
By Type, Targeted Radionuclide Drug market has been segmented into:
Medicine
Inhibitor
By Application, Targeted Radionuclide Drug market has been segmented into:
Tumors
Thyroid
Others
Regional Analysis of Targeted Radionuclide Drug Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Targeted Radionuclide Drug Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Targeted Radionuclide Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Targeted Radionuclide Drug market.
Top Key Companies Covered in Targeted Radionuclide Drug market are:
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Fusion Pharmaceuticals
RadioMedix
Inc.
Convergent Therapeutics
IONETIX
Clarity Pharmaceuticals
RayzeBio
Inc
AmbioPharm
Bracco Imaging
Navidea
China Isotope & Radiation Corporation
Yantai Dongcheng
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Targeted Radionuclide Drug Market by Type
5.1 Targeted Radionuclide Drug Market Overview Snapshot and Growth Engine
5.2 Targeted Radionuclide Drug Market Overview
5.3 Medicine
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Medicine: Geographic Segmentation
5.4 Inhibitor
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Inhibitor: Geographic Segmentation
Chapter 6: Targeted Radionuclide Drug Market by Application
6.1 Targeted Radionuclide Drug Market Overview Snapshot and Growth Engine
6.2 Targeted Radionuclide Drug Market Overview
6.3 Tumors
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Tumors: Geographic Segmentation
6.4 Thyroid
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Thyroid: Geographic Segmentation
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Targeted Radionuclide Drug Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Targeted Radionuclide Drug Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Targeted Radionuclide Drug Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 POINT BIOPHARMA
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 TELIX
7.4 ITM AG
7.5 BAYER AG
7.6 NOVARTIS
7.7 LANTHEUS
7.8 CURIUM PHARMA
7.9 FUSION PHARMACEUTICALS
7.10 RADIOMEDIX
7.11 INC.
7.12 CONVERGENT THERAPEUTICS
7.13 IONETIX
7.14 CLARITY PHARMACEUTICALS
7.15 RAYZEBIO
7.16 INC
7.17 AMBIOPHARM
7.18 BRACCO IMAGING
7.19 NAVIDEA
7.20 CHINA ISOTOPE & RADIATION CORPORATION
7.21 YANTAI DONGCHENG
7.22 GRAND PHARMA
7.23 HENGRUI MEDICINE
7.24 YUNNAN BAIYAO GROUP
7.25 SMARTNUCLIDE BIOPHARMA
7.26 SINOTAU
7.27 HEXIN PHARMACEUTICAL
Chapter 8: Global Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Medicine
8.2.2 Inhibitor
8.3 Historic and Forecasted Market Size By Application
8.3.1 Tumors
8.3.2 Thyroid
8.3.3 Others
Chapter 9: North America Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Medicine
9.4.2 Inhibitor
9.5 Historic and Forecasted Market Size By Application
9.5.1 Tumors
9.5.2 Thyroid
9.5.3 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Medicine
10.4.2 Inhibitor
10.5 Historic and Forecasted Market Size By Application
10.5.1 Tumors
10.5.2 Thyroid
10.5.3 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Medicine
11.4.2 Inhibitor
11.5 Historic and Forecasted Market Size By Application
11.5.1 Tumors
11.5.2 Thyroid
11.5.3 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Medicine
12.4.2 Inhibitor
12.5 Historic and Forecasted Market Size By Application
12.5.1 Tumors
12.5.2 Thyroid
12.5.3 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Medicine
13.4.2 Inhibitor
13.5 Historic and Forecasted Market Size By Application
13.5.1 Tumors
13.5.2 Thyroid
13.5.3 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Targeted Radionuclide Drug Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Medicine
14.4.2 Inhibitor
14.5 Historic and Forecasted Market Size By Application
14.5.1 Tumors
14.5.2 Thyroid
14.5.3 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Targeted Radionuclide Drug Scope:
|
Report Data
|
Targeted Radionuclide Drug Market
|
|
Targeted Radionuclide Drug Market Size in 2025
|
USD XX million
|
|
Targeted Radionuclide Drug CAGR 2025 - 2032
|
XX%
|
|
Targeted Radionuclide Drug Base Year
|
2024
|
|
Targeted Radionuclide Drug Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals, RadioMedix, Inc., Convergent Therapeutics, IONETIX, Clarity Pharmaceuticals, RayzeBio, Inc, AmbioPharm, Bracco Imaging, Navidea, China Isotope & Radiation Corporation, Yantai Dongcheng, Grand Pharma, Hengrui Medicine, Yunnan Baiyao Group, SmartNuclide Biopharma, Sinotau, Hexin Pharmaceutical.
|
|
Key Segments
|
By Type
Medicine
Inhibitor
By Applications
Tumors
Thyroid
Others
|
